Lung Ambition Alliance unveils new initiatives to address lung cancer survival at the World Conference on Lung Cancer
07 sept. 2019 10h00 HE
|
Lung Ambition Alliance
New grants program to support local initiatives driven by patient organizations that have the potential to transform patient care Series of interactive and educational exhibits at the congress to...
BioCardia Signs Exclusive Development Agreement With AstraZeneca
25 juil. 2019 06h00 HE
|
BioCardia, Inc.
SAN CARLOS, Calif., July 25, 2019 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced...
Hudson RPO and AstraZeneca win HRD magazine’s Innovative HR Team award
18 mars 2019 09h00 HE
|
Hudson Global, Inc.
SYDNEY, Australia, March 18, 2019 (GLOBE NEWSWIRE) -- Hudson RPO, along with its client, AstraZeneca Australia have been named Innovative HR Team winner by HRD magazine. The award recognises the...
Predictive Technology Group Appoints Dr. Gregory A. Prince to Its Scientific Advisory Board
17 janv. 2018 09h20 HE
|
PREDICTIVE TECHNOLOGY GROUP, INC.
SALT LAKE CITY, Jan. 17, 2018 (GLOBE NEWSWIRE) --
Predictive Technology Group, Inc. (OTC PINK:PRED), a leader in the use of data analytics for disease identification and subsequent...
Peregrine Pharmaceuticals Reports Financial Results for Quarter and Fiscal Year Ended April 30, 2016 and Recent Developments
14 juil. 2016 16h05 HE
|
Peregrine Pharmaceuticals Inc.
-- Avid Contract Manufacturing Revenues Increased 66% to $44.4 Million with a Revenue Backlog of $68 Million Heading into Fiscal Year 2017 ---- Growing Biomanufacturing Demand Prompts Plans for Third...
FEI Partners with Five Pharmaceutical Companies, the Medical Research Council and the University of Cambridge to form Cryo-EM Research Consortium
04 avr. 2016 06h05 HE
|
FEI Company
HILLSBORO, Ore. and LONDON, April 04, 2016 (GLOBE NEWSWIRE) -- FEI (NASDAQ:FEIC) has partnered with five pharmaceutical companies: Astex Pharmaceuticals, AstraZeneca, GlaxoSmithKline, Heptares...
Peregrine Pharmaceuticals Declares Quarterly Dividend on Its Series E Convertible Preferred Stock
07 mars 2016 16h05 HE
|
Peregrine Pharmaceuticals Inc.
TUSTIN, Calif., March 07, 2016 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) (Nasdaq:PPHMP) today announced that its Board of Directors has declared a quarterly cash dividend...
Peregrine to Report Financial Results for Third Quarter of Fiscal Year 2016 Prior to Market Open on March 9, 2016
03 mars 2016 16h05 HE
|
Peregrine Pharmaceuticals Inc.
TUSTIN, Calif., March 03, 2016 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the...
Peregrine Pharmaceuticals Provides Update on Planned Expansion of Bavituximab Clinical Program in Lung, Breast and Other Cancers
11 janv. 2016 08h05 HE
|
Peregrine Pharmaceuticals Inc.
-- Phase II Study in NSCLC in Collaboration with AstraZeneca Evaluating Bavituximab Plus Durvalumab to Expand Lung Cancer Program in Q1 2016 -- -- Phase II/III Study in HER2-Negative Metastatic...
AstraZeneca and Peregrine Pharmaceuticals Expand Ongoing Immuno-Oncology Collaboration to Include Phase II Lung Cancer Combination Clinical Trial
15 oct. 2015 08h05 HE
|
Peregrine Pharmaceuticals Inc.
TUSTIN, Calif., Oct. 15, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the...